ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 891,68
-0,19%
Dow Jones
44 677,77
0,27%
DAX
21 585,93
0,35%
Brent Oil
74,595
-1,77%
Bitcoin
98 161,26
0,31%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Chimerix Inc (CMRX)

  7. Chimerix Inc (CMRX) Actualités

CMRX

Chimerix (CMRX)

Chimerix Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CMRX
DateHeureSourceTitreSymboleSociété
31/01/202522h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CMRXChimerix Inc
30/01/202519h00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CMRXChimerix Inc
29/01/202522h15GlobeNewswire Inc.Chimerix to Present at JonesTrading Virtual Precision Medicine SymposiumNASDAQ:CMRXChimerix Inc
24/01/202522h01GlobeNewswire Inc.Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CMRXChimerix Inc
13/01/202513h00GlobeNewswire Inc.Chimerix to Speak Today at The White House Cancer Moonshot ForumNASDAQ:CMRXChimerix Inc
30/12/202413h21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CMRXChimerix Inc
30/12/202413h00GlobeNewswire Inc.Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse GliomaNASDAQ:CMRXChimerix Inc
10/12/202415h55AllPennyStocks.comSmall Cap Soars On FDA Submission PlansNASDAQ:CMRXChimerix Inc
09/12/202422h01GlobeNewswire Inc.Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-EndNASDAQ:CMRXChimerix Inc
11/11/202413h00GlobeNewswire Inc.Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO MeetingNASDAQ:CMRXChimerix Inc
07/11/202413h28Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CMRXChimerix Inc
07/11/202413h00GlobeNewswire Inc.Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational UpdateNASDAQ:CMRXChimerix Inc
01/11/202412h00GlobeNewswire Inc.Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024NASDAQ:CMRXChimerix Inc
18/10/202422h31GlobeNewswire Inc.Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CMRXChimerix Inc
03/09/202413h00GlobeNewswire Inc.Chimerix to Present at H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:CMRXChimerix Inc
13/08/202422h05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CMRXChimerix Inc
13/08/202413h00GlobeNewswire Inc.Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational UpdateNASDAQ:CMRXChimerix Inc
06/08/202413h00GlobeNewswire Inc.Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024NASDAQ:CMRXChimerix Inc
30/05/202413h00GlobeNewswire Inc.Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare ConferenceNASDAQ:CMRXChimerix Inc
06/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CMRXChimerix Inc
01/05/202413h00GlobeNewswire Inc.Chimerix Reports First Quarter 2024 Financial Results and Provides Operational UpdateNASDAQ:CMRXChimerix Inc
24/04/202413h00GlobeNewswire Inc.Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024NASDAQ:CMRXChimerix Inc
21/03/202412h00GlobeNewswire Inc.Chimerix Appoints Marc D. Kozin to Board of DirectorsNASDAQ:CMRXChimerix Inc
29/02/202415h20Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CMRXChimerix Inc
29/02/202414h24Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CMRXChimerix Inc
29/02/202413h00GlobeNewswire Inc.Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational UpdateNASDAQ:CMRXChimerix Inc
27/02/202413h00GlobeNewswire Inc.Chimerix to Present at TD Cowen 44th Annual Health Care ConferenceNASDAQ:CMRXChimerix Inc
22/02/202413h00GlobeNewswire Inc.Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024NASDAQ:CMRXChimerix Inc
14/02/202423h01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CMRXChimerix Inc
02/01/202417h07Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CMRXChimerix Inc
 Showing the most relevant articles for your search:NASDAQ:CMRX

Dernières Valeurs Consultées

ASX
EAGF
Ellerston Asia Growth
BOV
OXYP34Q
Occidental Petroleum
ASX
BASN
Bass Strait Oil
BOV
R2HH34
HR
BIT
WTI2L
SG ETC Daily Long 2X Wti...
BIT
S24552
SG ISSUER
BIT
AI4UJ
Fineco Artificial Intell...
EU
NL0013589336
Kingdom of Netherlands M...
BOV
COPH34Q
Conoco Phillips
LSE
66FK
Natwest.m 24
BIT
S28743
Societe Generale Effekten
BIT
S28779
Societe Generale Effekten
ASX
TA1HD
Transurban Finance Compa...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces